Catherine T. Doherty Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 4 days, 16 hours ago
Catherine T. Doherty has an estimated net worth of at least $33.7 million*, as of April 2, 2025. They own 68,068 shares of DGX stock. They have sold 144,838 shares of DGX stock since 2021, for an estimated $22.2 million.
Catherine T. Doherty $DGX SEC Form 4 Insider Trading
Catherine T. Doherty has filed a total of 22 insider trades in $DGX since 2021. Their most recent trade was a sale of 5,370 shares, made on Mar 05, 2025. Their largest trade was a sale of 28,300 shares, made on Nov 27, 2024. We estimate that they now own 68,068 shares of $DGX, worth an estimated $11.5 million.
Insider Trading at $DGX
There have been a total of 95 insider trades reported at $DGX since 2021, with 0 shares purchased and 973,710 shares sold. The most active insider traders in $DGX stock have been Stephen H Rusckowski, J. E. Davis, and Michael E Prevoznik. The most recent trade was a sale of 453 shares reported by J. E. Davis (CEO and President), made on Apr 02, 2025.
History of Insider Stock Trades by Catherine T. Doherty
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
DGX
|
Sale | 5,370 | Mar 05, 2025 | March 7, 2025, 8:23 p.m. |
|
DGX
|
Sale | 716 | Mar 04, 2025 | March 5, 2025, 5:38 p.m. |
|
DGX
|
Sale | 824 | Feb 27, 2025 | Feb. 28, 2025, 5:35 p.m. |
|
DGX
|
Sale | 899 | Feb 20, 2025 | Feb. 21, 2025, 5:41 p.m. |
|
DGX
|
Sale | 535 | Feb 19, 2025 | Feb. 21, 2025, 5:41 p.m. |
|
DGX
|
Sale | 4,803 | Nov 27, 2024 | Dec. 2, 2024, 5:41 p.m. |
|
DGX
|
Sale | 28,300 | Nov 27, 2024 | Dec. 2, 2024, 5:41 p.m. |
|
DGX
|
Sale | 1,187 | Feb 29, 2024 | March 1, 2024, 5:51 p.m. |
|
DGX
|
Sale | 5,557 | Feb 28, 2024 | March 1, 2024, 5:51 p.m. |
|
DGX
|
Sale | 821 | Feb 22, 2024 | Feb. 23, 2024, 5:32 p.m. |
|
DGX
|
Sale | 5,307 | Mar 07, 2023 | March 8, 2023, 5:38 p.m. |
|
DGX
|
Sale | 717 | Mar 03, 2023 | March 6, 2023, 6:08 p.m. |
|
DGX
|
Sale | 1,690 | Feb 24, 2023 | Feb. 27, 2023, 5:42 p.m. |
|
DGX
|
Sale | 17,358 | Nov 28, 2022 | Nov. 29, 2022, 5:35 p.m. |
|
DGX
|
Sale | 23,407 | Nov 28, 2022 | Nov. 29, 2022, 5:35 p.m. |
|
DGX
|
Sale | 7,032 | Mar 08, 2022 | March 9, 2022, 5:40 p.m. |
|
DGX
|
Sale | 2,750 | Feb 24, 2022 | Feb. 28, 2022, 8:50 p.m. |
|
DGX
|
Sale | 3,250 | Nov 29, 2021 | Dec. 1, 2021, 5:34 p.m. |
|
DGX
|
Sale | 15,908 | Nov 29, 2021 | Dec. 1, 2021, 5:34 p.m. |
|
DGX
|
Sale | 14,575 | Nov 29, 2021 | Dec. 1, 2021, 5:34 p.m. |
|
DGX
|
Sale | 300 | Nov 29, 2021 | Dec. 1, 2021, 5:34 p.m. |
|
DGX
|
Sale | 3,532 | Nov 29, 2021 | Dec. 1, 2021, 5:34 p.m. |
$DGX Executives and Stock Owners with Insider Trades
-
Stephen H Rusckowski, Chairman, CEO and President
-
J. E. Davis, CEO and President
-
Michael E Prevoznik, SVP & General Counsel
-
Catherine T. Doherty, EVP, Regional Businesses
-
Catherine T. Doherty, SVP, Group Exec. Clin. Fran.
-
Michael J Deppe, SVP, Corp. Controller & CAO
-
Catherine T. Doherty, SVP, Regional Businesses
-
Karthik Kuppusamy, SVP, Clinical Solutions
-
Mark E Delaney, SVP & Chief Commercial Officer
-
Michael J Deppe, VP, Corp. Controller & CAO
-
Patrick Plewman, SVP for Diagnostic Services
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.